Mumbai, India — April 28, 2026
Pharmaceutical major Sanofi India Limited and its demerged unit Sanofi Consumer Healthcare India reported their financial results for the first quarter of calendar year 2026 on Tuesday, showcasing mixed performance across segments.
As Sanofi follows a January–December financial year, the reported results correspond to Q1 2026.
Sanofi India: Stable Performance Led by Insulin Portfolio
Sanofi India delivered a steady performance during the quarter, supported by strong growth in its insulin portfolio.
- Revenue from operations stood at ₹472.3 crore, improving from ₹419.8 crore in the previous quarter
- Net profit was reported at ₹102.6 crore
The company’s insulin segment recorded double-digit growth, emerging as the key driver of overall performance.
In a significant leadership development, the board announced the appointment of Rahul Bhatnagar as Chairman, effective April 30, 2026.
Consumer Healthcare Arm Delivers Strong Growth
Sanofi’s consumer healthcare business posted robust growth across key metrics:
- Net profit surged 35.6% year-on-year to ₹67.8 crore
- Revenue rose 32.8% to ₹229.2 crore
The segment also saw exceptional export performance, with exports jumping 144.4%, while domestic sales grew 15.5%.
Operational efficiency improved significantly, with EBITDA margin expanding to 38.7%, highlighting strong profitability.
Market Reaction
Following the results, shares of Sanofi Consumer Healthcare India recorded gains, rising 1.31% on the BSE, reflecting investor optimism.
In contrast, shares of Sanofi India faced mild pressure during the trading session.
Outlook
The results highlight a divergence in performance between Sanofi’s core pharmaceutical business and its consumer healthcare segment. While the pharma unit continues to rely on steady insulin-driven growth, the consumer arm is emerging as a high-growth, high-margin business.
Investors will closely monitor upcoming quarters for sustained growth momentum and the impact of leadership changes on strategic direction.
